Prone Breast Irradiation for Pendulous Breasts
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00181363|
Recruitment Status : Unknown
Verified April 2007 by Maastricht Radiation Oncology.
Recruitment status was: Active, not recruiting
First Posted : September 16, 2005
Last Update Posted : April 27, 2007
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Device: Mamma board||Not Applicable|
Local excision followed by adjuvant radiotherapy has become standard treatment for women with early-stage breast cancer. Adjuvant radiotherapy may encounter technical difficulties in patients with pendulous breasts when treated in supine position.
Based upon literature and our own preliminary experiences, we hypothesize that for large pendulous breasts, breast irradiation in supine and prone position are equivalent with regard to coverage of the PTV, but with a better dose homogeneity in prone position and a smaller radiation exposure of lung and heart. However, no quantitative data are yet available to test this hypothesis. Therefore, the aim of our study is to compare the 3-D dose distribution in PTV and normal tissues in prone position versus supine position.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mamma Board Project: Prone Breast Irradiation for Pendulous Breasts|
|Study Start Date :||December 2003|
|Estimated Study Completion Date :||January 2010|
- In 10 patients a conventional simulation will be done in supine and prone position. A planning CT-scan will be obtained in both positions. A lead wire will be placed around the palpable breast tissue as an aid in the delineation.
- Volume of the CTV (cc),Maximum dose delivered in at least 1 cc,Minimum dose in PTV, delivered in at least 1% of the PTV
- PTV coverage (% of PTV < 95% of prescribed dose),Doses in organs at risk (heart: V30, V40, V50, lung: V20, MLD)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00181363
|Maastricht Radiation Oncology|
|Heerlen, Limburg, Netherlands, 6419 PC|
|Principal Investigator:||Jeroen Buijsen, MD||Maastricht Radiation Oncology|